Solid biosciences provides first quarter 2021 business update and financial results

- patients 7 and 8 dosed in ignite-dmd phase i/ii clinical trial under new clinical protocol and second-generation sgt-001 manufacturing process; patient 8 experienced a serious adverse event -
SLDB Ratings Summary
SLDB Quant Ranking